Supplemental table 4. Heart rate data not contributing to meta-analyses Randomized trials, nicotine EC v comparator group

Study ID	Intervention/ comparator	Time point	Data										Between group difference¹ (↑ higher in EC/higher dose EC arm; ↔ equivocal; ↓ lower in EC/higher dose arm)
George 2019	Nicotine EC v non-nicotine EC	4 weeks	"No significant trend in difference among the three arms" Broke down results by smoking characteristics at baseline. Smoked ≤20 pack years (n=31): increased by 2.6 beats/min (95% CI: 0.3 to 5.0) for EC-nicotine; 5.2 beats/min (95% CI: 0.6 to 10.0) for nicotine-free. >20 pack-years (n = 82): decreased by 2.8 beats/min (95% CI: -5.2 to -0.4) for EC nicotine; decreased by 5.6 beats/min (95% CI: -10.4 to -0.8) for no-nicotine EC								\leftrightarrow		
Veldheer 2019	EC (nicotine, non- nicotine groups combined) v QuitSmart cigarette substitute	12 weeks	Group	Baseline Mean	SD	N	4 weeks Mean (change)	SD	N	12 weeks Mean (change)	SD	N	↑
			Sub EC	79.6 82.1	13.2	72 191	-1.73	12.97 11.32	72 191	-1.89 -0.86	12.29 14.18	72 191	
Walele 2018	Nicotine EC versus conventional cigarette	2 weeks	"no clinic	cally signi	ificant o	change	es"						NE

¹ NE: not estimable

Studies in which all groups received nicotine EC with no between-group difference in concentration

Study ID Hickling	Time point	Data Moan: baseline S	Direction over time² (↓ decline; ↔ equivocal; ↑ increase)									
2019	weeks ³	Mean: baseline 80.65 bpm (SD 16.01); week 6 82 bpm, SD 15.76 (n=46)										
Ikonomidis	1	Group	Baseline			1 Month				Mixed across		
2018 ⁴	month		Mean	SD	N	Mean	SD	N		groups		
		E Cig+con-cig	70	9	24	72	8	24				
		E-cig only	73	8	42	70	7	42				
		Noncompliant	71	8	4	70	8	4				
		Controls	71	8	20	70	8	20				
Oncken	2	"no significant ch	\leftrightarrow									
2015	weeks											
Van Staden	2	"no significant ch	\leftrightarrow									
2013	weeks			•					1	1		
Walele 2018 ⁵	2 years	Timepoint		Mea	n		SD		N	↓		
		Baseline		72.3			10.8		206			
		Month 1		71.4			9.7		184			
		Month 6		71.6			9.9		141			
		Month 12		71.1 69.1			11.1					
		Month 18					10.9		104			
		Month 24		70.4			11.4		102			

² NE: not estimable

³ EC provided for 6 weeks; HR measured at weeks 1-10 and 24

⁴ Acute crossover trial followed by 'chronic phase' so treated as cohort for purposes of this review

⁵ Short term RCT (see first table); all participants then given nicotine EC hence inclusion in this table, as well